ReviewPharmaceuticals (Basel, Switzerland)2026
Analytical Methods for Melatonin Quantification: Advances, Challenges, and Clinical Applications.
Review in Pharmaceuticals (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Melatonin inhibits malignant biological behaviors in carboplatin-resistant ovarian cancer cells: elucidating the potential molecular mechanisms.Molecular biology reports · 2026Article
- Circadian control of immune homeostasis in cardiovascular health and disease.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Melatonin, an indoleamine crucial for regulating circadian rhythms, sleep-wake cycles, and immune-endocrine homeostasis, is present in biological fluids at extremely low concentrations, making its quantification analytically challenging. This narrative review provides a critical comparative assessment of current methodologies for melatonin determination across various biological matrices-plasma, urine, saliva, breast milk, and hair. The discussed techniques include immunoassays, colorimetric and spectrophotometric methods, chromatographic-mass spectrometric platforms (LC-MS/MS, UHPLC-MS/MS), and emerging biosensors. Each approach is evaluated regarding analytical sensitivity, specificity, reproducibility, cost, and clinical applicability. While immunoenzymatic and colorimetric techniques offer accessible, low-cost solutions for large-scale or preliminary studies, LC-MS/MS remains the benchmark for reference analysis, providing sub-picogram detection limits and multiplexing capability. However, its high cost, procedural complexity, and inter-laboratory variability limit routine implementation. New developments, including molecularly imprinted polymers, dispersive microextraction, and nanomaterial-based biosensors, suggest a shift toward hybrid, sustainable, and portable analytical platforms. By synthesizing recent methodological advances and identifying key limitations, this review aims to guide researchers and clinicians in selecting the most appropriate analytical approach for clinical, pharmacological, and circadian biomonitoring applications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.